Company Overview
Snapshot
Founded in January 2008 by Ehud Marom, Mapi Pharma operates with 51–200 employees. The company has raised a total of $42.5 million across 4 funding rounds from 3 investors. In September 2022, Mapi Pharma announced positive top-line results from its GA Depot Phase III trial for Relapsing forms of Multiple Sclerosis (RMS).
Business overview
Mapi Pharma is a clinical-stage pharmaceutical company focused on developing proprietary pharmaceuticals, including lifecycle management products such as long-acting injections and complex active pharmaceutical ingredients. Its core technology involves formulations for conditions like multiple sclerosis, neuropathic pain, epilepsy, and schizophrenia. The company's lead product is Glatiramer Acetate Depot, a once-monthly injection for multiple sclerosis, and it also develops Pregabalin ER. Mapi Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the pharmaceutical industry.
Strategic signal
In September 2022, Mapi Pharma announced positive top-line results from its GA Depot Phase III trial for Relapsing forms of Multiple Sclerosis (RMS). This milestone indicates significant progress in the clinical development of its lead product, validating its potential efficacy and advancing the company closer to market approval. For investors, this signals a de-risking event and potential for future commercialization in a high-value therapeutic area.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant clinical trial update for Mapi Pharma's lead product?
- In September 2022, Mapi Pharma announced positive top-line results from its GA Depot Phase III trial for Relapsing forms of Multiple Sclerosis (RMS).
- Which patent did Mapi Pharma receive in March 2022?
- In March 2022, Mapi Pharma received a U.S. patent covering methods of suppressing or alleviating primary or secondary progressive Multiple Sclerosis with a sustained-release Glatiramer Acetate Depot.
- When did Mapi Pharma sign an agreement to market and distribute its products in the UAE?
- In October 2021, Mapi Pharma signed an agreement with Gaelan Medical Trade LLC to exclusively market and distribute Mapi products in the UAE.
- When did Mapi Pharma present results for Glatiramer Acetate Depot (GA Depot) at a major medical meeting?
- In September 2020, Mapi Pharma presented Glatiramer Acetate Depot (GA Depot) results at the 8th Joint ACTRIMS-ECTRIMS Meeting MSVirtual2020.
- What was a key investment Mapi Pharma received in November 2018?
- In November 2018, Mapi Pharma announced the closing of a $10 million investment by Zhejiang Jingxin Pharmaceutical Co.